Corpus overview


Overview

MeSH Disease

Ageusia (22)

Fever (14)

Infections (12)

Cough (11)

Disease (7)


Human Phenotype

Anosmia (22)

Fever (14)

Cough (11)

Fatigue (6)

Headache (6)


Transmission

Seroprevalence
    displaying 1 - 10 records in total 24
    records per page




    Determinants of SARS-CoV-2 infection MESHD in Italian healthcare workers: a multicenter study

    Authors: Paolo Boffetta; Francesco Violante; Paolo Durando; Giuseppe De Palma; Enrico Pira; Luigi Vimercati; Alfonso Cristaudo; Giancarlo Icardi; Emma Sala; Maurizio Coggiola; Silvio Tafuri; Vittorio Gattini; Pietro Apostoli; Giovanna Spatari; - Working Group on SARS-CoV-2 infection in Italian healthcare workers

    doi:10.1101/2020.07.29.20158717 Date: 2020-07-30 Source: medRxiv

    Background. Healthcare workers (HCW) are at increased risk of being infected with SARS-CoV-2, yet limited information is available on risk factors of infection MESHD. Methods. We pooled data on occupational surveillance of 10,654 HCW who were tested for SARS-CoV-2 infection MESHD in six Italian centers. Information was available on demographics, job title, department of employment, source of exposure, use of personal protective equipment (PPE), and COVID-19-related symptoms. We fitted multivariable logistic regression models to calculate odds ratios (OR) and 95% confidence intervals (CI). Findings. The prevalence SERO of infection MESHD varied across centers and ranged from 3.0% to 22.0%, being strongly correlated with that of the respective areas. Women were at lower risk of infection TRANS risk of infection TRANS infection MESHD compared to men. Fever MESHD Fever HP, cough MESHD cough HP, dyspnea MESHD dyspnea HP and malaise were the symptoms most strongly associated with infection MESHD, together with anosmia HP and ageusia MESHD. No differences in the risk of infection TRANS risk of infection TRANS infection MESHD were detected between job titles, or working in a COVID-19 designated department. Reported contact with a patient inside or outside the workplace was a risk factor. Use of a mask was strongly protective against risk of infection TRANS risk of infection TRANS infection MESHD as was use of gloves. The use of a mask by the source of exposure (patient or colleague) had an independent effect in reducing infection MESHD infection risk TRANS infection risk TRANS risk.

    Evidence of gender TRANS bias in the diagnosis and management of COVID-19 patients: A Big Data analysis of Electronic Health Records

    Authors: Julio Ancochea; Jose L. Izquierdo; - Savana COVID-19 Research Group; Joan B Soriano

    doi:10.1101/2020.07.20.20157735 Date: 2020-07-26 Source: medRxiv

    Background: It remains unknown whether the frequency and severity of COVID-19 affect women differently than men. Here, we aim to describe the characteristics of COVID-19 patients at disease MESHD onset, with special focus on the diagnosis and management of female TRANS patients with COVID-19. Methods: We explored the unstructured free text in the electronic health records (EHRs) within the SESCAM Healthcare Network (Castilla La-Mancha, Spain). The study sample comprised the entire population with available EHRs (1,446,452 patients) from January 1st to May 1st, 2020. We extracted patients' clinical information upon diagnosis, progression, and outcome for all COVID-19 cases. Results: A total of 4,780 patients with a test-confirmed diagnosis of COVID-19 were identified. Of these, 2,443 (51%) were female TRANS, who were on average 1.5 years younger than males TRANS (61.7{+/-}19.4 vs. 63.3{+/-}18.3, p=0.0025). There were more female TRANS COVID-19 cases in the 15-59 yr.-old interval, with the greatest sex ratio (SR; 95% CI) observed in the 30-39 yr.-old interval (1.69; 1.35-2.11). Upon diagnosis, headache MESHD headache HP, anosmia HP, and ageusia MESHD were significantly more frequent in females TRANS than males TRANS. Imaging by chest X-ray or blood SERO tests were performed less frequently in females TRANS (65.5% vs. 78.3% and 49.5% vs. 63.7%, respectively), all p<0.001. Regarding hospital resource use, females TRANS showed less frequency of hospitalization (44.3% vs. 62.0%) and ICU admission (2.8% vs. 6.3%) than males TRANS, all p<0.001. Conclusion: Our results indicate important sex-dependent differences in the diagnosis, clinical manifestation, and treatment of patients with COVID-19. These results warrant further research to identify and close the gender TRANS gap in the ongoing pandemic.

    Prevalence SERO of Anosmia HP and Ageusia MESHD in Patients with COVID-19 at a Primary Health Center, Doha, Qatar

    Authors: Raid Muhmid Al-Ani; DEBASHIS ACHARYA

    doi:10.21203/rs.3.rs-48737/v1 Date: 2020-07-25 Source: ResearchSquare

    Background: Loss of smell and taste are common complaints in patients with the COVID-19 disease MESHD. These symptoms may present alone or with other symptoms. It is of utmost importance to know their rates of occurrence for better controlling of the infection MESHD. Objectives: To detect the prevalence SERO of anosmia HP and ageusia MESHD in individuals with COVID-19 in Al-Wajbah Primary Health Center, Doha, Qatar.Materials and methods: This retrospective study was conducted at Al-Wajbah Primary Health Center, Doha, Qatar. The study covered the two-month period -May and June 2020. The proven cases of COVID-19 by real-time PCR (Polymerase Chain Reaction) were enrolled in the study. Data regarding the age TRANS, gender TRANS, symptomatology including anosmia HP and ageusia MESHD, history of recent travel TRANS, smoking, past history of nasal and paranasal diseases MESHD (NPND), and severity of the disease MESHD were taken from the patients’ records. IBM- SPSS version 22 statistical software was used for the analysis of the data.Results: Out of 141, 35 (24.82%) subject presented with anosmia HP, ageusia MESHD or both. Most of the patients were from age group TRANS >30 year (n=104, 73.76%) with nearly equal gender TRANS. The majority of the individuals were without history of recent travel TRANS (92.2%) and smoking (80.14%). Three-quarters of the patients were asymptomatic TRANS, and 51.06% with a past history of NPND. The male TRANS sex, history of recent travel TRANS, smoking, and severe course of the disease MESHD were positive, highly significant association with anosmia HP or ageusia MESHD. All patients returned to their normal smell and taste sensations within a mean duration of 6.89 days.Conclusion: Loss of taste and smell were common symptomatology of COVID-19 disease MESHD. The males TRANS, recent travel TRANS, smoking, and severe course of the disease MESHD were risk factors of the anosmia HP and ageusia MESHD in COVID-19 cases.

    Stringent thresholds for SARS-CoV-2 IgG assays result in under-detection of cases reporting loss of taste/smell

    Authors: David W Eyre; Sheila F Lumley; Nicole E Stoesser; Philippa C Matthews; Alison Howarth; Stephanie B Hatch; Brian D Marsden; Stuart Cox; Tim James; Richard Cornall; David I Stuart; Gavin Screaton; Daniel Ebner; Derrick W Crook; Christopher P Conlon; Katie Jeffery; Timothy M Walker; Tim EA Peto

    doi:10.1101/2020.07.21.20159038 Date: 2020-07-25 Source: medRxiv

    Thresholds for SARS-CoV-2 antibody SERO assays have typically been determined using samples from symptomatic, often hospitalised, patients. Assay performance SERO following mild/ asymptomatic infection MESHD asymptomatic TRANS is unclear. We assessed IgG responses in asymptomatic TRANS healthcare workers with a high pre-test probability of Covid-19, e.g. 807/9292(8.9%) reported loss of smell/taste. The proportion reporting anosmia HP/ ageusia MESHD increased at antibody SERO titres below diagnostic thresholds for both an in-house ELISA SERO and the Abbott Architect chemiluminescent microparticle immunoassay SERO (CMIA): 424/903(47%) reported anosmia HP/ ageusia MESHD with a positive ELISA SERO, 59/387(13.2%) with high-negative titres, and 324/7943(4.1%) with low-negative results. Adjusting for the proportion of staff reporting anosmia HP/ ageusia MESHD suggests the sensitivity SERO of both assays is lower than previously reported: Oxford ELISA SERO 90.8% (95%CI 86.1-92.1%) and Abbott CMIA 80.9% (77.5-84.3%). However, the sensitivity SERO may be lower if some anosmia HP/ ageusia MESHD in those with low-negative titres is Covid-19-associated. Samples from individuals with mild/ asymptomatic infection MESHD asymptomatic TRANS should be included in SARS-CoV-2 immunoassay SERO evaluations. Reporting equivocal SARS-CoV-2 antibody SERO results should be considered.

    Hiccups MESHD and Psychosis HP: Two atypical presentations of COVID -19

    Authors: Teresa Alvarez-Cisneros; Aldo Lara-Reyes; Stephanie Sansón-Tinoco

    doi:10.21203/rs.3.rs-48043/v1 Date: 2020-07-23 Source: ResearchSquare

    The WHO defines a possible case of COVID-19 as a person experiencing fever MESHD fever HP, cough MESHD cough HP, shortness of breath and neurological signs including anosmia HP, ageusia MESHD or dysgeusia MESHD. However, experiences from hospitals all over the world have shown that presentations vary widely. In our emergency MESHD department in a private hospital in Mexico City, we received two patients with very different symptoms on the same shift. Two previously healthy men in their 40 s presented, one with 3 days of hiccups MESHD and the other with a new onset psychotic event.

    Olfactory and gustatory dysfunction in 2019 novel coronavirus: An updated systematic review and meta-analysis

    Authors: Marzieh Esmaeili; Fatemeh Abdi; Gita Shafiee; Hadis Rastad; Hamid Asayesh; Zahra Esmaeili Abdar; Fereshteh Baygi; Mostafa Qorbani

    doi:10.21203/rs.3.rs-44648/v1 Date: 2020-07-17 Source: ResearchSquare

    BackgroundEvidence showed that partial or complete loss of smell and taste might be a possible primary symptom of the 2019 novel coronavirus (COVID-19). This study aimed to systematically review and pool all available evidence on the olfactory and gustatory dysfunction in COVID-19 patients. MethodsIn this systematic review, a comprehensive search was carried out systematically through e-databases including PubMed, EMBASE, Scopus, and Web of Science (WoS); that was limited to English-language studies published from 2019 up to 6th May 2020. Afterward, all studies reported the taste and smell dysfunction in the COVID-19 patients were included. The quality of the studies was assessed by the Mixed Methods Appraisal Tool (MMAT). The pooled prevalence SERO of olfactory and gustatory dysfunction was estimated using the random effects meta-analysis method.ResultsAmong 28 eligible included studies in this systematic review, finally, 22 studies met the eligibility criteria and were included in the meta-analysis. According to the random effect meta-analysis, the global pooled prevalence SERO (95% confidence interval) of any olfactory dysfunction, anosmia HP, and hyposmia HP was 55% (40%-70%), 40% (22%-57%), and 40% (20%-61%) respectively. The pooled estimated prevalence SERO of any gustatory dysfunction, ageusia MESHD, and dysgeusia MESHD was 41% (23%-59%), 31% (3%-59%), and 34% (19%-48%) respectively. ConclusionOlfactory and gustatory dysfunction is prevalent among COVID-19 patients. Therefore, olfactory and gustatory dysfunction seems to be part of important symptoms and notify for the diagnosis of COVID-19, especially in the early phase of the infection MESHD.

    Early Attention Impairment in a Patient with COVID-19

    Authors: Júlio César Tolentino; Ana Lúcia Taboada Gjorup; Guilherme Janeiro Schmidt; Sergio Luis Schmidt

    id:10.20944/preprints202007.0271.v1 Date: 2020-07-12 Source: preprints.org

    A 47-year-old physician suddenly noticed a persistent difficulty maintaining attention. He was awake, alert, and oriented. After two hours he developed fever MESHD fever HP, ageusia MESHD, and anosmia HP. He denied any previous history of psychiatric illness and was hydrated at the time of the subjective attention impairment. On admission, the patient remained oriented. He reported the persistence of attention problems, anosmia HP, and mild fatigue MESHD fatigue HP. The oxygen saturation 99% while he was breathing ambient air. Laboratory tests were unremarkable. A high-resolution computed tomography of the chest was normal. Nasopharyngeal and throat swabs specimens on reverse transcription-polymerase chain reaction analysis tested positive for SARS-CoV2. On illness day 3, the examination was unchanged, but he continued to complain of difficulties to stay focused. Then, he performed an objective attention test. The test demonstrated a moderate attentional impairment. On day 6, the patient reported a subjective worse in his concentration and performed a second test. Although his physical examination remained normal, the attention performance SERO was worse as compared to day 3. Eight hours after worsening of attention impairment, the patient’s oxygen saturation dropped to 94%. From illness days 9 to 14, the patient evolved with clinical improvement. On day 10, a third objective attention test indicated a mild deficit. On day 16, he did not report any other symptom and the attention test was completely normal. Then, the patient returned to work. Neurological symptoms had been previously described in COVID- 19 patients. However, no previous research had investigated early cognitive deficits preceding the traditional symptoms.

    Risk Factors Prediction, Clinical Outcomes, and Mortality of COVID-19 Patients

    Authors: Roohallah Alizadehsani; Zahra Alizadeh sani; Mohaddeseh Behjati; Zahra Roshanzamir; Sadiq Hussain; Niloofar Abedini; Fereshteh Hasanzadeh; Abbas Khosravi; Afshin Shoeibi; Mohamad Roshanzamir; Pardis Moradnejad; Saeid Nahavandi; Fahime Khozeimeh; Assef Zare; Maryam Panahiazar; U. Rajendra Acharya; Sheikh Mohammed Shariful Islam

    doi:10.1101/2020.07.07.20148569 Date: 2020-07-09 Source: medRxiv

    Background: Preventing communicable diseases MESHD requires understanding the spread, epidemiology, clinical features, progression, and prognosis of the disease MESHD. Early identification of risk factors and clinical outcomes might help to identify critically ill patients, provide proper treatment and prevent mortality. Methods: We conducted a prospective study in patients with flu-like symptoms referred to the imaging department of a tertiary hospital in IRAN between 3 March 2020 and 8 April 2020. Patients with COVID-19 were followed up to check their health condition after two months. The categorical data between groups were analyzed by Fisher exact test and continuous data by Wilcoxon Rank-Sum Test. Findings: 319 patients (mean age TRANS 45.48 years, 177 women) were enrolled. Fever MESHD Fever HP, dyspnea MESHD dyspnea HP, weakness, shivering HP, C-reactive protein (CRP), fatigue MESHD fatigue HP, dry cough MESHD cough HP, anorexia MESHD anorexia HP, anosmia HP, ageusia MESHD, dizziness MESHD, sweating and age TRANS were the most important symptoms of COVID-19 infection MESHD. Traveling TRANS in past three months, asthma MESHD asthma HP, taking corticosteroids, liver disease MESHD, rheumatological disease MESHD, cough MESHD cough HP with sputum, eczema MESHD eczema HP, conjunctivitis MESHD conjunctivitis HP, tobacco use, and chest pain MESHD chest pain HP did not have any relationship with COVID-19. Interpretation: Finding clinical symptoms for early diagnosis of COVID-19 is a critical part of prevention. These symptoms can help in the assessment of disease progression MESHD. To the best of our knowledge, some of the effective features on the mortality due to COVID-19 are investigated for the first time in this research. Funding: None

    Reconstructing the global dynamics of under-ascertained COVID-19 cases and infections MESHD

    Authors: Nick Golding; Timothy W Russell; Sam Abbott; Joel Hellewell; Carl A B Pearson; Kevin van Zandvoort; Christopher I Jarvis; Hamish Gibbs; Yang Liu; Rosalind M Eggo; John W Edmunds; Adam J Kucharski

    doi:10.1101/2020.07.07.20148460 Date: 2020-07-08 Source: medRxiv

    Background: Asymptomatic TRANS or subclinical SARS-CoV-2 infections MESHD are often unreported, which means that confirmed case TRANS counts may not accurately reflect underlying epidemic dynamics. Understanding the level of ascertainment (the ratio of confirmed symptomatic cases to the true number of symptomatic individuals) and undetected epidemic progression is crucial to informing COVID-19 response planning, including the introduction and relaxation of control measures. Estimating case ascertainment over time allows for accurate estimates of specific outcomes such as seroprevalence SERO, which is essential for planning control measures. Methods: Using reported data on COVID-19 cases and fatalities globally, we estimated the proportion of symptomatic cases (i.e. any person with any of fever MESHD fever HP >= to 37.5C, cough MESHD cough HP, shortness of breath, sudden onset of anosmia HP, ageusia MESHD or dysgeusia MESHD illness) that were reported in 210 countries and territories, given those countries had experienced more than ten deaths MESHD. We used published estimates of the case fatality ratio (CFR) as an assumed baseline. We then calculated the ratio of this baseline CFR to an estimated local delay-adjusted CFR to estimate the level of under-ascertainment in a particular location. We then fit a Bayesian Gaussian process model to estimate the temporal pattern of under-ascertainment. Results: We estimate that, during March 2020, the median percentage of symptomatic cases detected across the 84 countries which experienced more than ten deaths MESHD ranged from 2.38% (Bangladesh) to 99.6% (Chile). Across the ten countries with the highest number of total confirmed cases TRANS as of 6th July 2020, we estimated that the peak number of symptomatic cases ranged from 1.4 times (Chile) to 17.8 times (France) larger than reported. Comparing our model with national and regional seroprevalence SERO data where available, we find that our estimates are consistent with observed values. Finally, we estimated seroprevalence SERO for each country. Despite low case detection in some countries, our results that adjust for this still suggest that all countries have had only a small fraction of their populations infected as of July 2020. Conclusions: We found substantial under-ascertainment of symptomatic cases, particularly at the peak of the first wave of the SARS-CoV-2 pandemic, in many countries. Reported case counts will therefore likely underestimate the rate of outbreak growth initially and underestimate the decline in the later stages of an epidemic. Although there was considerable under-reporting in many locations, our estimates were consistent with emerging serological data, suggesting that the proportion of each country's population infected with SARS-CoV-2 worldwide is generally low.

    SARS-CoV-2 exposure, symptoms and seroprevalence SERO in health care workers

    Authors: Ann-Sofie Rudberg; Sebastian Havervall; Anna Manberg; August Jernbom Falk; Katherina Aguilera; Henry Ng; Lena Gabrielsson; Ann-Christin Salomonsson; Leo Hanke; Benjamin Murell; Gerald McInerney; Jennie Olofsson; Eni Andersson; Cecilia Hellstrom; Shaghayegh Bayati; Sofia Bergstrom; Elisa Pin; Ronald Sjoberg; Hanna Tegel; My Hedhammar; Mia Phillipson; Peter Nilsson; Sophia Hober; Charlotte Thalin

    doi:10.1101/2020.06.22.20137646 Date: 2020-06-23 Source: medRxiv

    Background: SARS-CoV-2 may pose an occupational health risk to health care workers, but the prevalence SERO of infections MESHD in this population is unknown. We examined the seroprevalence SERO of SARS-CoV-2 antibodies SERO among health care workers at a large acute care hospital in Stockholm, Sweden. We determined correlations between seroprevalence SERO, self-reported symptoms and occupational exposure to SARS-CoV-2. Methods and findings: All employees at Danderyd Hospital (n=4375) were invited to participate in a cross-sectional study. 2149 employees from all hospital departments were enrolled in the study between April 14th and May 8th 2020. Study participants completed a questionnaire consisting of symptoms compatible with SARS-CoV-2 infection MESHD since January 2020 and occupational exposure to patients infected with SARS-CoV-2. IgG antibodies SERO against SARS-CoV-2 were analyzed using a multiplex assay evaluated to have 99.4% sensitivity SERO and 99.1% specificity. The over-all seroprevalence SERO among 2149 participants was 19.1% (n=410). There was no difference in age TRANS or sex between seropositive and seronegative participants. The symptoms with the strongest correlation to seroprevalence SERO were anosmia HP and ageusia MESHD, with odds ratios of 28.4 (p=2.02*10^-120) and 19.2 (p=1.67*10^-99) respectively. Seroprevalence SERO was strongly associated with patient-related work (OR 2.9, p=4.24*10^-8), covid-19 patient contact (OR 1.43, p=0.003), and occupation as assisting nurse (OR 3.67, p=2.16*10^-9). Conclusion: These results demonstrate that anosmia HP and ageusia MESHD should be included in screening guidance and in the recommendations of self-isolation to reduce further spread of SARS-CoV-2. The results furthermore imply an occupational health risk for SARS-CoV-2 infection MESHD among hospital workers. Continued measures are warranted to assure healthcare worker safety and reduce transmission TRANS from health care settings to the community during the covid-19 outbreak.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.